Today, Signet Therapeutics (hereinafter referred to as "Signet") announced that the company's core pipeline SIGX1094...Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). As part of the FDA's special accelerated review mechanism for new drugs targeting serious diseases or unmet clinical needs, this designation is expected to significantly shorten the approval timeline for SIGX1094, expedite its market entry, and bring a new treatment option to patients worldwide. This marks a new qualification following the FDA Orphan Drug Designation (ODD) granted to SIGX1094 in November 2024.
SIGX1094 is the core product developed by Signet Therapeutics based on its innovative "organoid + AI" drug discovery platform, primarily used for treating diffuse gastric cancer and other advanced solid tumors. This drug is based on a novel therapeutic target independently discovered by Signet Therapeutics, combined with XtalPi's AI + robotics drug discovery platform, making it not only a global...The First Class I Innovative Drug Integrating Organoid and AI Technology Development, and at the same time isA Breakthrough Drug with the Potential to Fill the Gap in Targeted Therapy for Diffuse Gastric CancerCurrently, the first patient has been dosed with SIGX1094 at Peking University Cancer Hospital. The Phase I clinical trial is being led by Professor Shen Lin, an authoritative expert in the field of gastrointestinal tumors.
After receiving the FDA Fast Track designation, SIGX1094 will have more opportunities to communicate with the FDA during the subsequent development and approval process, which will significantly accelerate its market entry. Drugs that receive this designation also have the opportunity to enjoyAccelerated approval, priority review status, and rolling review of Biologics License Applications (BLA), etc.Preferential policies.
SIGNET is the first in China to adopt an innovative cancer targeted drug R&D model that combines "organoids + AI." The company has a deep collaboration with XtalPi, using AI technology to quickly screen candidate compound molecules. It also relies on SIGNET's exclusive organoid disease model platform for efficacy evaluation and testing. This innovative model not only significantly accelerates the speed of drug development and increases clinical success rates but also marks the entry of drug R&D into a new era of efficient IT and BT integration.
About SIGNET
SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a National High-Tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since secured nearly 220 million yuan in funding and project grants. Signet Therapeutics currently has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China’s NMPA, along with Orphan Drug Designation and Fast Track Designation from the U.S. FDA, and has now entered Phase I clinical trials.
Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Full of Hope, Investigating Things to Gain Knowledge." The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and new target discovery. Combined with AI-powered screening, synthesis, and optimization of small-molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has a 1200㎡ R&D facility and a 500㎡ experimental animal housing area. SIGNET’s organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.
1
END
1
